Paper Details

  1. Home
  2. Paper Details

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.

Author: , ButlerKathleen, DesaiSeemal R, EzzedineKhaled, GrimesPearl, HarrisJohn E, KornackiDeanna, LebwohlMark, PandyaAmit G, PasseronThierry, RosmarinDavid, Ruer-MulardMireille, SeneschalJulien, SunKang, WolkerstorferAlbert

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Ruxolitinib cream was found to be more effective than vehicle control in repigmenting vitiligo lesions in two phase 3 trials. The cream resulted in a 75% reduction in the facial Vitiligo Area Scoring Index (F-VASI) in 29.8% of patients in TRuE-V1 and 30.9% of patients in TRuE-V2 compared to 7.4% and 11.4% in the vehicle control groups, respectively. However, the cream was associated with acne and pruritus at the application site. Larger and longer trials are needed to determine the long-term effects and safety of ruxolitinib cream in patients with vitiligo.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A cream formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in repigmentation in a phase 2 trial involving adults with vitiligo. METHODS: We conducted two phase 3, double-blind, vehicle-cont...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa2118828

データ提供：米国国立医学図書館（NLM）

Ruxolitinib Cream: A New Hope for Vitiligo Patients

Vitiligo, a chronic autoimmune disease characterized by skin depigmentation, can significantly impact a patient's self-esteem and quality of life. This study explores the potential of ruxolitinib cream, a novel topical treatment, to promote repigmentation in patients with vitiligo. The findings from two phase 3 trials, TRuE-V1 and TRuE-V2, demonstrate that ruxolitinib cream significantly improved facial repigmentation compared to a vehicle control, leading to a clinically meaningful improvement in the Vitiligo Area Scoring Index. While the treatment was associated with some common adverse events, such as application-site acne and pruritus, it holds promise as a new therapeutic option for patients with vitiligo.

Ruxolitinib Cream: A Potential Game Changer in Vitiligo Treatment

The study's findings suggest that ruxolitinib cream could be a valuable addition to the therapeutic arsenal for vitiligo. The observed improvement in facial repigmentation is a significant step forward in managing this challenging condition. While further research is needed to fully assess the long-term efficacy and safety of this treatment, it offers hope for patients seeking relief from vitiligo's disfiguring effects.

A New Dawn for Vitiligo Treatment: More Options, More Hope

Imagine the relief and joy that a patient with vitiligo would experience upon seeing their skin regaining its natural pigmentation. This research brings us closer to that reality, offering new hope for those struggling with this challenging condition. It's a reminder that medical innovation continues to advance, providing new options and possibilities for individuals with vitiligo and their families.

Dr.Camel's Conclusion

Vitiligo can feel like a desert storm, stripping away a person's sense of self and confidence. This research, like a refreshing oasis, provides a glimmer of hope. Ruxolitinib cream, with its potential to restore pigmentation, offers a chance to weather the storm and reclaim a sense of wholeness. It's a testament to the dedication of researchers who tirelessly search for solutions to improve the lives of those affected by chronic conditions.

Date :
  1. Date Completed 2022-10-24
  2. Date Revised 2023-08-07
Further Info :

Pubmed ID

36260792

DOI: Digital Object Identifier

10.1056/NEJMoa2118828

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.